Abstract:Background: Cardiac hypertrophy and its associated remodeling are among the leading causes of heart failure. Lysine crotonylation is a recently discovered posttranslational modification whose role in cardiac hypertrophy remains largely unknown. NAE1 (NEDD8-activating enzyme E1 regulatory subunit) is mainly involved in the neddylation modification of protein targets. However, the function of crotonylated NAE1 has not been defined. This study aims to elucidate the effects and mechanisms of NAE1 crotonylation on cardiac hypertrophy. Methods: Crotonylation levels were detected in both human and mouse subjects with cardiac hypertrophy through immunoprecipitation and Western blot assays. TMT-labeled quantitative lysine crotonylome analysis was performed to identify the crotonylated proteins in a mouse cardiac hypertrophic model induced by transverse aortic constriction. We generated NAE1 knock-in mice carrying a crotonylation-defective lysine to arginine K238R (lysine to arginine mutation at site 238) mutation (NAE1 K238R) and NAE1 knock-in mice expressing a crotonylation-mimicking lysine to glutamine K238Q (lysine to glutamine mutation at site 238) mutation (NAE1 K238Q) to assess the functional role of crotonylation of NAE1 at K238 in pathological cardiac hypertrophy. Furthermore, we combined coimmunoprecipitation, mass spectrometry, and dot blot analysis that was followed by multiple molecular biological methodologies to identify the target GSN (gelsolin) and corresponding molecular events contributing to the function of NAE1 K238 crotonylation. Results: The crotonylation level of NAE1 was increased in mice and patients with cardiac hypertrophy. Quantitative crotonylomics analysis revealed that K238 was the main crotonylation site of NAE1. Loss of K238 crotonylation in NAE1 K238R knock-in mice attenuated cardiac hypertrophy and restored the heart function, while hypercrotonylation mimic in NAE1 K238Q knock-in mice significantly enhanced transverse aortic constriction-induced pathological hypertrophic response, leading to impaired cardiac structure and function. The recombinant adenoviral vector carrying NAE1 K238R mutant attenuated, while the K238Q mutant aggravated Ang II (angiotensin II)-induced hypertrophy. Mechanistically, we identified GSN as a direct target of NAE1. K238 crotonylation of NAE1 promoted GSN neddylation and, thus, enhanced its protein stability and expression. NAE1 crotonylation-dependent increase of GSN promoted actin-severing activity, which resulted in adverse cytoskeletal remodeling and progression of pathological hypertrophy. Conclusions: Our findings provide new insights into the previously unrecognized role of crotonylation on nonhistone proteins during cardiac hypertrophy. We found that K238 crotonylation of NAE1 plays an essential role in mediating cardiac hypertrophy through GSN neddylation, which provides potential novel therapeutic targets for pathological hypertrophy and cardiac remodeling.

NDRG1 regulates iron metabolism and inhibits pathological cardiac hypertrophy

Neuregulin-1β Partially Improves Cardiac Function in Volume-Overload Heart Failure Through Regulation of Abnormal Calcium Handling.

Overexpression Of Nrdp1 In The Heart Exacerbates Doxorubicin-Induced Cardiac Dysfunction In Mice

Downregulation of the (pro)renin receptor alleviates ferroptosis-associated cardiac pathological changes via the NCOA 4-mediated ferritinophagy pathway in diabetic cardiomyopathy

Nuclear Receptor Corepressor 1 Represses Cardiac Hypertrophy

Gene transfer of human neuregulin-1 attenuates ventricular remodeling in diabetic cardiomyopathy rats.

Up-regulation of P27kip1 Contributes to Nrf2-mediated Protection Against Angiotensin II-induced Cardiac Hypertrophy

NDRG1 Promotes Endothelial Dysfunction and Hypoxia-Induced Pulmonary Hypertension by Targeting TAF15

Therapeutic effects of neuregulin-1 in diabetic cardiomyopathy rats

Crotonylation of NAE1 Modulates Cardiac Hypertrophy via Gelsolin Neddylation

Ndufa7 Plays a Critical Role in Cardiac Hypertrophy

Novel Role of Mitochondrial GTPases 1 in Pathological Cardiac Hypertrophy

Effects of Neuregulin-1 on Ventricular Remolding in Experimental Diabetic Cardiomyopathy

Notoginsenoside R1 attenuates ischemic heart failure by modulating MDM2/β arrestin2-mediated β2-adrenergic receptor ubiquitination

Neuregulin-1, a potential therapeutic target for cardiac repair

Reduced DNMT1 Levels Induce Cell Apoptosis Via Upregulation of METTL3 in Cardiac Hypertrophy

NDRG1 acts as an oncogene in triple-negative breast cancer and its loss sensitizes cells to mitochondrial iron chelation

Inhibition of Nogo-B Promotes Cardiac Hypertrophy Via Endoplasmic Reticulum Stress

Detrimental Role of PDZ-RhoGEF in Pathological Cardiac Hypertrophy

Improvement of Cardiac Function and Reversal of Gap Junction Remodeling by Neuregulin-1β in Volume-Overloaded Rats with Heart Failure

Effect of NLRP3 gene knockdown on pyroptosis and ferroptosis in diabetic cardiomyopathy injury